Neurophth

Private

WuhanHealthcare & Life Scienceshttps://www.neurophth.com/

Last Round

Series C

Extension

Aug 11, 2023

Est. Valuation

$700M

Total Funding Raised

$240.67M

Company Overview

Neurophth is a biotechnology company that develops gene therapies for the treatment of ophthalmological disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene therapyadeno-associated virusAAVophthalmic gene therapyinherited retinal diseasesbiotechclinical-stage biotechcGMP manufacturingGMPrare disease treatmentorphan drugclinical trialsLeber's hereditary optic neuropathyLHONgenetic eye disorders

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Neurophth Comps

Public and private peers based on sector, stage, and business model.

Neurophth comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Neurophth Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series C Extension	Aug 11, 2023
Series C	Nov 23, 2021
Series B	Feb 9, 2021
Series A	Apr 9, 2020
Angel	Aug 1, 2018
Angel	Jul 1, 2018

View all Funding Rounds

Key People

Founding team and executive leadership

Su Xiao

Co-Founder, Chief Technical Operations Officer, Board Member

Founding Team

Luke Li

CEO Deputy GM Of SH SZ Branch Head Of Com Ops Director Of BoD, VP, Strategy, BD Alliances, GA And Commercialization Deputy GM, Neurophth Shanghai Branch

Executive Team

Neurophth Investors

Notable investors and investment history

Neurophth investors
Investor	Rounds
Huaxin Investment China InnoVision Capital	Series B
Oriza Holdings	Series B
招银国际金融有限公司	Series C
Northern Light Venture Capital	Angel, Series B, Series A
InnoVision Capital	Series B
InnoStar Capital	Series A
Shanghai International Group	Series B

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Feb 9, 2021
$62M round led by Huaxin Investment China InnoVision Capital.
Aug 1, 2018
$3.07M raised, led by Miracle Light Venture.

View all signals

Neurophth Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Neurophth Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Neurophth's valuation, stock price, and market status.

Firmographic Details

HeadquartersWuhan

Employee Range38

Year Founded2016

Last FundingAug 11, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.